ImmunityBio (NASDAQ:IBRX) Stock Price Up 5.9% – Here’s Why
by Amy Steele · The Cerbat GemImmunityBio, Inc. (NASDAQ:IBRX – Get Free Report) shot up 5.9% on Monday . The company traded as high as $8.22 and last traded at $8.1550. 4,670,553 shares were traded during mid-day trading, a decline of 87% from the average session volume of 34,831,793 shares. The stock had previously closed at $7.70.
Key Stories Impacting ImmunityBio
Here are the key news stories impacting ImmunityBio this week:
- Neutral Sentiment: The company’s founder publicly backed a policy initiative and also highlighted new Anktiva breast‑cancer risk data; the story mixes political publicity with an ambiguous data signal that could prompt investor attention but is not a clear positive or negative catalyst on its own. Article Title
- Negative Sentiment: Lowey Dannenberg announced an investigation into potential federal securities law violations at ImmunityBio — this raises the prospect of regulatory scrutiny, discovery, and litigation expense that can pressure the stock. Article Title
- Negative Sentiment: Multiple securities class actions have been filed and several firms (Kessler Topaz, Hagens Berman and others) are soliciting lead‑plaintiff applicants for the January 19–March 24, 2026 class period; Hagens Berman’s notice ties the suits to an FDA warning letter about allegedly misleading efficacy claims for Anktiva — litigation risk plus potential regulatory findings are material to future revenue and reputation. Article Title
- Negative Sentiment: Several additional plaintiff firms (Faruqi & Faruqi, Robbins Geller, DJS Law Group, Bronstein, Rosen, etc.) issued investor reminders about the May 26, 2026 lead‑plaintiff deadline — widespread legal interest increases probability of consolidated litigation and potential settlement exposure. Article Title
Wall Street Analyst Weigh In
Several equities research analysts have issued reports on the stock. D. Boral Capital reaffirmed a “buy” rating and set a $23.00 price target on shares of ImmunityBio in a research note on Wednesday, April 8th. HC Wainwright raised their price target on shares of ImmunityBio from $10.00 to $15.00 and gave the stock a “buy” rating in a research note on Monday, February 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of ImmunityBio in a report on Tuesday, April 14th. Piper Sandler reiterated an “overweight” rating and issued a $12.00 price target (up from $7.00) on shares of ImmunityBio in a report on Wednesday, March 4th. Finally, BTIG Research began coverage on ImmunityBio in a report on Thursday, March 12th. They issued a “buy” rating and a $13.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $14.40.
Read Our Latest Stock Analysis on ImmunityBio
ImmunityBio Trading Up 6.7%
The business has a 50 day simple moving average of $8.00 and a 200-day simple moving average of $4.74. The stock has a market capitalization of $8.44 billion, a price-to-earnings ratio of -21.59 and a beta of 0.13.
ImmunityBio (NASDAQ:IBRX – Get Free Report) last issued its quarterly earnings results on Monday, February 23rd. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.02. The business had revenue of $38.29 million during the quarter. Research analysts predict that ImmunityBio, Inc. will post -0.92 EPS for the current year.
Insider Activity at ImmunityBio
In related news, Director Christobel Selecky sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $10.00, for a total transaction of $250,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Barry J. Simon sold 165,000 shares of ImmunityBio stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $10.25, for a total value of $1,691,250.00. Following the completion of the transaction, the director owned 2,925,821 shares in the company, valued at $29,989,665.25. The trade was a 5.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 451,967 shares of company stock valued at $4,216,412 in the last ninety days. 69.48% of the stock is currently owned by company insiders.
Institutional Trading of ImmunityBio
Institutional investors and hedge funds have recently bought and sold shares of the business. Slow Capital Inc. acquired a new stake in ImmunityBio during the 3rd quarter worth approximately $25,000. Truist Financial Corp acquired a new position in shares of ImmunityBio during the 3rd quarter valued at $27,000. Swiss Life Asset Management Ltd acquired a new position in shares of ImmunityBio during the 3rd quarter valued at $27,000. WealthPlan Investment Management LLC acquired a new position in shares of ImmunityBio during the 4th quarter valued at $27,000. Finally, Diversify Advisory Services LLC acquired a new position in shares of ImmunityBio during the 2nd quarter valued at $27,000. Institutional investors and hedge funds own 8.58% of the company’s stock.
About ImmunityBio
ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.
Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.